1. Home
  2. CNTX vs GANX Comparison

CNTX vs GANX Comparison

Compare CNTX & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Context Therapeutics Inc.

CNTX

Context Therapeutics Inc.

N/A

Current Price

$0.17

Market Cap

47.7M

Sector

Health Care

ML Signal

N/A

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

N/A

Current Price

$1.05

Market Cap

52.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CNTX
GANX
Founded
2015
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.7M
52.2M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
CNTX
GANX
Price
$0.17
$1.05
Analyst Decision
Buy
Strong Buy
Analyst Count
10
5
Target Price
$3.79
★ $6.60
AVG Volume (30 Days)
★ 1.2M
693.7K
Earning Date
11-10-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
17.39
★ 31.46
EPS
N/A
★ N/A
Revenue
N/A
★ $55,180.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.15
$0.94
52 Week High
$3.62
$4.34

Technical Indicators

Market Signals
Indicator
CNTX
GANX
Relative Strength Index (RSI) 36.02 40.82
Support Level N/A $0.94
Resistance Level $0.22 $1.91
Average True Range (ATR) 0.02 0.13
MACD 0.00 0.02
Stochastic Oscillator 33.07 26.37

Price Performance

Historical Comparison
CNTX
GANX

About CNTX Context Therapeutics Inc.

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: